Latest News

Mavenclad® Cladribine – Have your Say by Friday 22nd September 2023

September 19, 2023 | Treatments

Mavenclad® Cladribine – Have your Say MSNZ is currently preparing a submission to Pharmac to urge them to again consider funding Mavenclad (Cladribine) for Relapsing Remitting MS. Our submission is due this Friday 22nd September. Real world and clinical trial […]


Media Release: “Relief” over Pharmac Decision to Fund First-Ever Treatment for Debilitating Form of Multiple Sclerosis

September 4, 2023 | Advocacy, Media, Progressive, Treatments

A seven year battle on behalf of hundreds of people living with the most debilitating form of Multiple Sclerosis has been won – with Pharmac agreeing to fund Aotearoa New Zealand’s first ever treatment for the disease variant  from October […]


MS in the News: Funded treatment for primary progressive multiple sclerosis

June 26, 2023 | Media, Progressive

Te Pātaka Whaioranga – Pharmac has started a consultation today for widening access for two treatments; ocrelizumab (branded as Ocrevus) as the first funded treatment for primary progressive multiple sclerosis, and emicizumab (branded as Hemlibra) for the treatment of all […]


Major announcement: Pharmac Initiates Consultation to fund Ocrelizumab for Primary Progressive MS.

June 22, 2023 | Advocacy, Funding, Media, Progressive

Multiple Sclerosis New Zealand (MSNZ) is delighted to share that Pharmac have commenced consultation to fund Ocrelizumab for Primary Progressive MS. Currently, those with PPMS have no access to any disease modifying therapies. Ocrelizumab has been proven in trials to […]


Calling all people with Secondary Progressive MS

July 26, 2022 | Life with MS, Progressive, Research

Multiple Sclerosis NZ is currently in the process of providing information to Pharmac regarding the high unmet need of those with Secondary Progressive MS. A new treatment, Siponimod (Mayzent), is currently under review and due to be assessed by PTAC […]